Neurocrine Biosciences
NBIX
$159.76
-1.81%
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders, with a portfolio including therapies for tardive dyskinesia, Huntington's disease chorea, and classic congenital adrenal hyperplasia. The company has established itself as a commercial-stage leader in movement disorders and endocrinology, leveraging its expertise to build a sustainable revenue base from its flagship products. The current investor narrative is dominated by a strategic pivot towards high-growth rare diseases, highlighted by the recent acquisition of Soleno Therapeutics, juxtaposed against near-term pressures from conservative sales guidance for its key drug, Ingrezza, which has sparked debate about the balance between long-term pipeline strength and immediate financial performance.…
NBIX
Neurocrine Biosciences
$159.76
Related headlines
Investment Opinion: Should I buy NBIX Today?
Rating & Thesis: The synthesized recommendation is a Buy, based on the thesis that Neurocrine's strong profitability, robust cash flow, and strategic pivot into high-growth rare diseases justify its premium valuation, with significant earnings growth priced into an attractive forward P/E, aligning with unanimous analyst bullish sentiment.
Supporting Evidence: This Buy rating is supported by four key data points: 1) A compelling forward P/E of 13.17x, implying 124% earnings growth and a discount to its own trailing multiple, 2) Robust revenue growth of 28.33% YoY, 3) Exceptional profitability metrics including a 97.82% gross margin and $748.7M in TTM free cash flow, and 4) A pristine balance sheet with a 3.39 current ratio and minimal debt, providing a low-risk financial profile for growth funding.
Risks & Conditions: The two biggest risks that could invalidate the thesis are a further deceleration in Ingrezza sales growth below 20% YoY and failed integration of the Soleno acquisition. This Buy rating would downgrade to Hold if the forward P/E expanded above 20x without corresponding earnings growth acceleration, or downgrade to Sell if quarterly revenue growth decelerated into the low teens. The stock is fairly valued relative to its near-term earnings potential but carries a premium on trailing earnings that demands flawless execution.
Sign up to view all
NBIX 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The core of the thesis rests on the large valuation gap between trailing and forward earnings, which demands execution but offers substantial upside if achieved. The company's financial fortress (strong cash flow, no debt) significantly de-risks the investment compared to typical biotechs. However, confidence is tempered to 'medium' due to the near-term overhang from Ingrezza guidance and the stock's extended technical position near 52-week highs. The stance would upgrade to 'bullish with high confidence' on confirmation of Ingrezza sales stabilization in the next quarter, or downgrade to 'neutral' if the forward P/E expands above 16x without an earnings beat.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $207.69 and implied upside of +30.0% versus the current price.
Average Target
$207.69
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$128 - $208
Analyst target range
Analyst coverage is active with 7 firms providing estimates, and institutional ratings from firms like JP Morgan, Wells Fargo, and RBC Capital show a unanimously bullish sentiment, with all recent actions being reiterations of 'Buy', 'Overweight', or 'Outperform' ratings. The consensus average revenue estimate for the next period is $5.43 billion, with a wide range from $4.79 billion to $6.20 billion, indicating high conviction in growth but some uncertainty around the magnitude. While a specific consensus price target is not provided in the data, the sustained bullish ratings following a guidance-driven sell-off suggest analysts see the current price levels as an attractive entry point for the long-term story. The wide range between the low and high revenue estimates ($4.79B to $6.20B, a 29.5% spread) signals significant uncertainty, likely stemming from modeling the impact of the Soleno acquisition and the trajectory of Ingrezza sales. The high-end estimates likely assume successful integration and faster-than-expected adoption of new therapies, while the low end may factor in competitive pressures or integration challenges. The pattern of reiterated bullish ratings after negative news is a strong signal of underlying fundamental strength and long-term confidence from the analyst community.
Bulls vs Bears: NBIX Investment Factors
The evidence currently leans bullish, supported by robust fundamentals, strong cash generation, and unanimous analyst confidence. The most compelling bull arguments are the company's transition to a profitable cash-generating entity and the significant earnings growth implied by its low forward P/E. However, the bear case is anchored in valid near-term concerns regarding growth sustainability after conservative guidance and the premium valuation on a trailing basis. The single most important tension in the investment debate is the resolution of near-term revenue trajectory for Ingrezza against the long-term promise and integration of the Soleno acquisition. If Ingrezza growth stabilizes and Soleno's pipeline delivers, the bull thesis is validated; if Ingrezza decelerates further or integration stumbles, the premium valuation becomes unjustified.
Bullish
- Strong Profitability & Cash Flow: The company generates substantial free cash flow of $748.7M TTM and boasts a high net margin of 19.08% in Q4 2025. This financial strength, coupled with a debt-to-equity ratio of just 0.13, provides ample resources for funding growth initiatives like the Soleno acquisition without financial strain.
- Accelerating Revenue Growth: Revenue grew 28.33% YoY in Q4 2025 to $805.5M, confirming a strong commercial franchise. This robust growth, driven almost entirely by product sales, demonstrates successful execution and market penetration for its core therapies.
- Compelling Forward Valuation: The forward P/E of 13.17x is significantly lower than the trailing P/E of 29.49x, implying the market expects a ~124% increase in earnings. This valuation gap prices in a major earnings inflection, potentially from the Soleno acquisition and continued core growth, offering upside if delivered.
- Unanimous Analyst Bullishness: All 7 covering analysts maintain bullish ratings (Buy/Overweight), even after a guidance-driven sell-off. This sustained confidence, with an average forward revenue estimate of $5.43B, signals strong long-term conviction in the company's strategy and pipeline.
Bearish
- Near-Term Growth Uncertainty: Q4 2025 revenue of $805.5M declined sequentially from Q3's $794.9M, and conservative 2026 guidance for flagship drug Ingrezza has already triggered a 10.6% single-day drop. This introduces questions about the sustainability of near-term growth rates.
- Premium Trailing Valuation: A trailing P/E of 29.49x is at a premium to the broader biotech sector and above its own recent historical average of 22.95x from Q4 2025. This elevated multiple raises the bar for flawless execution and leaves little room for disappointment.
- Revenue Concentration Risk: Product revenue of $798.3M constituted 99.1% of total Q4 revenue, with minimal collaboration income. This extreme reliance on commercial drug sales, primarily Ingrezza, exposes the company to product-specific competitive or reimbursement pressures.
- Extended Technical Positioning: Trading at $167.35, the stock is near its all-time high of $169.57, representing 98.7% of the 52-week range. This leaves it vulnerable to a technical pullback, with the 52-week low providing a -27% downside to $122.14.
NBIX Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 34.40% 1-year price change, but is currently trading near the top of its 52-week range, with the current price of $167.35 representing approximately 98.7% of the 52-week high of $169.57. This positioning near all-time highs suggests strong momentum but also raises concerns about potential overextension and vulnerability to a pullback. Recent short-term momentum is exceptionally strong and accelerating, with the stock up 23.91% over the past month and 30.61% over the past three months, significantly outpacing the broader market's 4.6% and 12.6% gains over the same periods, indicating powerful stock-specific catalysts. The key technical levels are clear, with immediate resistance at the 52-week high of $169.57 and support at the 52-week low of $122.14; a decisive breakout above resistance could signal a continuation of the powerful uptrend, while a failure could lead to consolidation. The stock's beta of 0.336 indicates it is significantly less volatile than the overall market, which is unusual for a biotech but suggests it is currently trading more on fundamental execution than speculative pipeline news.
Beta
0.40
0.40x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$122-$170
Price range past year
Annual Return
+27.8%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | -0.1% |
| 3m | +23.1% | +12.0% |
| 6m | +4.6% | +8.8% |
| 1y | +27.8% | +22.9% |
| ytd | +13.6% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Revenue growth is robust but showed some sequential deceleration in the most recent quarter; Q4 2025 revenue was $805.5 million, representing a 28.33% year-over-year increase, though this was down from the $794.9 million reported in Q3 2025. The growth is overwhelmingly driven by the Product segment, which contributed $798.3 million, while Collaboration Revenue was a minimal $7.2 million, indicating the company's success is tied to the commercial execution of its own drugs, primarily Ingrezza. The revenue trajectory confirms a strong commercial franchise, though the recent quarterly dip and conservative guidance have introduced questions about near-term growth sustainability. The company is solidly profitable with expanding margins; Q4 2025 net income was $153.7 million, yielding a net margin of 19.08%, while the gross margin remained exceptionally high at 97.82%. Operating income for the quarter was $210.9 million, translating to a healthy operating margin of 26.18%, demonstrating the company's ability to convert strong revenues into substantial earnings. The profitability profile is strong for a biotech, moving beyond the R&D-heavy loss-making phase into a sustainably profitable commercial entity. The balance sheet is exceptionally healthy with low leverage and strong cash generation; the debt-to-equity ratio is a minimal 0.128, and the company holds $721 million in cash with a robust current ratio of 3.39. Trailing twelve-month free cash flow is a substantial $748.7 million, providing ample internal funding for growth initiatives like the Soleno acquisition without straining the balance sheet. Return on equity of 14.71% indicates efficient use of shareholder capital, underpinning a low-financial-risk investment profile.
Quarterly Revenue
$805500000.0B
2025-12
Revenue YoY Growth
+0.28%
YoY Comparison
Gross Margin
+0.97%
Latest Quarter
Free Cash Flow
$748700000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Given a positive net income of $153.7 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 29.49x, while the forward PE is significantly lower at 13.17x, indicating the market expects a substantial near-term earnings growth of approximately 124% based on current analyst estimates. This large gap suggests the stock is priced for a major earnings inflection, likely tied to the integration of new acquisitions and continued core product growth. Compared to the broader biotechnology sector, a trailing PE of 29.5x is at a premium, but this is justified by Neurocrine's unique position as a profitable, commercial-stage company with a diversified portfolio, unlike many pre-revenue biotechs. The premium valuation reflects the lower risk profile and visible earnings stream, though it also raises the bar for execution. Historically, the stock's own trailing PE has ranged widely; the current 29.5x is above the 22.95x seen at the end of Q4 2025 but well below peaks above 80x in early 2024 when earnings were minimal. Trading above its recent historical average suggests the market is pricing in improved and more stable profitability, but investors should be aware that it is not at bargain-basement levels relative to its own history, demanding continued growth to justify the multiple.
PE
29.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -277x~349x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Neurocrine's primary financial risk is revenue concentration, with 99.1% of Q4 2025 sales coming from its product segment, heavily reliant on Ingrezza. While profitability is strong (19.1% net margin), the sequential quarterly revenue decline from $794.9M to $805.5M and conservative guidance introduce earnings volatility risk. The company's low debt-to-equity of 0.13 and strong cash position mitigate balance sheet risk, but the valuation premium demands continued high growth, creating pressure if execution falters.
Market & Competitive Risks: The stock trades at a trailing P/E premium (29.5x) to the biotech sector, creating valuation compression risk if growth decelerates or market sentiment sours on growth stocks. Its low beta of 0.336 suggests it trades more on fundamentals than speculation, but this also means it may not benefit from sector-wide rallies. The key competitive risk is the dependence on Ingrezza's market position, where new entrants or pricing pressures could directly impact the core revenue stream, as hinted by the recent guidance cut.
Worst-Case Scenario: The worst-case scenario involves a combination of Ingrezza sales missing already lowered guidance, coupled with integration challenges or clinical setbacks from the Soleno acquisition. This could trigger multiple compression and significant analyst downgrades. Quantifying the downside, the stock could realistically retreat to its 52-week low of $122.14, representing a -27% decline from the current price of $167.35. A drawdown of this magnitude is plausible given the stock's historical max drawdown of -20.9% and the recent sharp sell-off on guidance news.
FAQ
The key risks are, in order of severity: 1) Revenue Concentration Risk: Over 99% of revenue comes from product sales, primarily Ingrezza, making the company vulnerable to a single product's performance. 2) Execution Risk: The recent Soleno acquisition must be integrated successfully, and its pipeline must deliver to justify the strategic pivot. 3) Valuation Risk: The trailing P/E premium of 29.5x could compress if growth decelerates, exposing the stock to a pullback towards its 52-week low of $122.14. 4) Guidance Risk: The company has already issued conservative 2026 guidance; further misses could severely damage investor confidence.
The 12-month forecast for NBIX is framed by three scenarios. The Base Case (55% probability) sees the stock trading between $155 and $180 as it meets current earnings estimates. The Bull Case (30% probability) targets $185 to $210 on successful execution and multiple expansion. The Bear Case (15% probability) warns of a drop to $122-$145 if growth disappoints. The Base Case is most likely, anchored on the assumption that the company delivers on its forward EPS estimate of $14.89, justifying its current forward multiple. The wide analyst revenue estimate range ($4.79B to $6.20B) underscores the uncertainty in this forecast.
NBIX's valuation presents a dual narrative. On a trailing basis, it appears overvalued with a P/E of 29.49x, which is above both its sector and its own recent historical average. However, on a forward-looking basis, it appears undervalued with a forward P/E of just 13.17x, which prices in massive near-term earnings growth. This gap suggests the market is paying a fair price for expected future performance but a premium for past performance. The valuation implies the market expects flawless execution on both core product growth and the new Soleno pipeline to justify the current price.
NBIX presents a compelling risk/reward profile for investors comfortable with biotech sector dynamics. The stock is a good buy for those who believe in the company's ability to deliver on the significant earnings growth implied by its forward P/E of 13.17x, which is a 124% increase from trailing earnings. The unanimous bullish analyst sentiment and strong cash flow generation of $748.7M TTM provide supportive evidence. However, it is less suitable for highly risk-averse investors due to its premium trailing valuation (29.5x P/E) and dependence on the successful integration of the Soleno acquisition.
NBIX is more suitable for a long-term investment horizon of 2-3 years. While it has shown strong short-term momentum (+23.91% in 1 month), its investment thesis is based on the multi-year integration of the Soleno acquisition and the sustained growth of its commercial franchise. The stock's low beta of 0.336 suggests it is less suited for short-term trading based on market volatility. The lack of a dividend further emphasizes a growth-oriented, long-term holding strategy. Investors should be prepared to hold through potential volatility related to quarterly earnings and clinical trial updates to realize the value from its strategic pivot.